There are 86 papers on metabolic dysfunction-associated fatty liver disease in aging research: 7 trials and 49 observational studies in people, 10 in animals, 1 in cells, 18 reviews. The newest story, Nov 9, 2026: “Gene variants linked to higher odds of fatty liver disease”.
Human studies link metabolic dysfunction-associated fatty liver disease with higher mortality, incident chronic kidney disease and physical disability. They also associate it with PhenoAge acceleration and a retinal microvascular aging index; in patients with osteopenia, it is linked with worse physical function and higher oxidative stress.
58 findings in 34 papers from 2022 to 2026, 9 of them since May 2026
“Young adults with MAFLD had a 1.30 (95% CIs 1.26-1.35) and 1.40 (1.23-1.59) times higher prevalence of low- and high-risk adenomas, respectively, compared to those without MAFLD.”
Dietary modification prevents metabolic dysfunction-associated fatty liver disease in humans.
“The recommended dietary strategies emphasize adherence to a balanced diet with controlled energy intake and personalized nutritional interventions, such as calorie restriction, high-protein, or low-carbohydrate diets.”
Metabolic dysfunction-associated fatty liver disease is linked with worse mitochondrial fission and fusion in patients with osteopenia.
“peripheral blood macrophages in patients with MAFLD with more unbalanced mitochondrial dynamics of macrophages, more weakened mitochondrial respiratory capacity, and greater mitochondrial microstructure damage”
Humansin patients with osteopeniamacrophagesn = 107
Metabolic dysfunction-associated fatty liver disease is linked with worse physical function in patients with osteopenia (P = 0.012 (6MWD), P = 0.0029 (SPPB)).
“six-minute walking distance (P = 0.012) and short physical performance battery (SPPB) score (P = 0.0029) of the elderly OPe patients with MAFLD are worse than those in OPe patients without MAFLD”
European journal of gastroenterology & hepatology·
Snoring is linked with a higher risk of metabolic dysfunction-associated fatty liver disease in humans after full adjustments including obesity (OR 1.59 (95% CI 1.33, 1.91)).
“snoring, and daytime napping for over 30 minutes significantly associated with an increased risk of MAFLD, with odds ratios (OR) of 1.37 (95% CI 1.10, 1.70), 1.59 (95% CI 1.33, 1.91)”
Metabolic dysfunction-associated fatty liver disease is linked with a higher risk of mortality in humans (aHR 1.18, 95% CI 1.04-1.33).
“both MAFLD and MASLD were associated with increased risk of all-cause mortality (adjusted hazard ratio [aHR] 1.18, 95% CI 1.04-1.33 and 1.19, 1.06-1.34, respectively)”
Liver international : official journal of the International Association for the Study of the Liver·
PhenoAgeAccel
↑upin humans1OR 1.66
1 study
PhenoAgeAccel predicts metabolic dysfunction-associated fatty liver disease in humans (discrimination of MAFLD) (AUC = 0.622).
“PhenoAgeAccel demonstrated better discriminative ability (AUC = 0.622) than traditional fibrosis scores (FIB-4, NFS, BARD), with a high negative predictive value (88.8%).”
PhenoAgeAccel is linked with a higher risk of metabolic dysfunction-associated fatty liver disease in humans (case-control analysis, multivariable adjustment) (OR 1.66, 95% CI: 1.56-1.77).
“In the case-control analysis, each 5-year increase in PhenoAgeAccel was associated with 66% higher odds of MAFLD after multivariable adjustment (OR = 1.66, 95% CI: 1.56-1.77).”
TyG-BMI is linked with a higher risk of metabolic dysfunction-associated fatty liver disease in humans (multivariable logistic regression) (OR = 3.7, 95% CI: 3.05-4.48).
“TyG-BMI demonstrating the strongest association (OR = 3.7, 95% CI: 3.05-4.48).”
APOB is linked with a higher risk of metabolic dysfunction-associated fatty liver disease in humans (Heterozygous APOB pLoF carriers in HRN; validated across all cohorts) (OR=3.2).
“and elevated risk for MAFLD (OR=3.2), which validated across all cohorts.”
HumansHeterozygous APOB pLoF carriers in HRN; validated across all cohortslivern = 449
Skeletal muscle mass to visceral fat area ratio is associated with metabolic dysfunction-associated fatty liver disease in humans (routine health examination population; prevalent disease).
“SVR showed a strong inverse association with MAFLD (OR = 0.383, 95% CI: 0.368–0.399).”
Humansroutine health examination population; prevalent diseasen = 11,977
Life's Crucial 9 is associated with metabolic dysfunction-associated fatty liver disease in humans (prevalent MAFLD) (OR 0.51 per 10-point increase, 95% CI 0.47–0.56).
“every 10-point increase in the LC9 score was associated with lower odds of MAFLD”
Metabolic dysfunction-associated fatty liver disease is associated with incident chronic kidney disease in humans (CKD defined as eGFR < 60 ml/min/1.73 m 2) (26% increased risk; HR 1.26, 95% CI 1.11–1.43).
“MAFLD was associated with a 26% increased risk of incident CKD (hazard ratio: 1.26, 95% CI: 1.11–1.43; P < 0.001).”
HumansCKD defined as eGFR < 60 ml/min/1.73 m 2kidneyMedian follow-up 15.4 years
In 402,437 people, variants disrupting one copy of a fat-transport gene were linked to higher fatty liver odds, with an odds ratio of 3.2 versus non-carriers.In 402,437 people, variants disrupting one copy of a fat-transport gene were linked to higher fatty liver odds, with an odds ratio of 3.2 versus non-carriers.
Experiments linked a chemical change in a cell-recycling protein to exercise-related improvements in insulin responses and liver fat metabolism.Experiments linked a chemical change in a cell-recycling protein to exercise-related improvements in insulin responses and liver fat metabolism.